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AbstrACt
Objective To examine the effect of smoking on risk 
of atherosclerotic cardiovascular disease (ASCVD) in 
Korean young men and to examine whether serum total 
cholesterol levels could modify the effect of smoking on 
ASCVD.
Design A prospective cohort study within a national 
insurance system.
setting Health screenings provided by national insurance 
in 1992 and 1994.
Participants A total of 118 531 young men between 20 
and 29 years of age and were followed up for an average 
of 23 years.
Outcome measure To assess the independent effects 
of smoking on the risk of ischaemic heart disease (IHD), 
stroke and ASCVD, Cox proportional hazards regression 
models were used, controlling for age, hypertension, 
diabetes, hypercholesterolaemia and alcohol drinking.
results The total number of current smokers was 78 455 
(66.2%), and 94 113 (79.7%) of the sample recorded a 
total cholesterol level <200 mg/dL measured at baseline. 
Between 1993 and 2015, 2786 cases of IHD (53/100 000 
person year), 2368 cases of stroke (45.4/100 000 person 
year) and 6368 ASCVD (122.7/100 000 person year) 
occurred. The risk of IHD, stroke and total ASCVD events 
was found to increase for current smokers, with a HR with 
95% CI of 1.5 (95% CI 1.3 to 1.6), 1.4 (95% CI 1.2 to 1.6) 
and 1.4 (95% CI 1.3 to 1.5), respectively. Furthermore, 
the risks above were also found throughout the range of 
serum levels of cholesterol.
Conclusions Smoking among Korean young adult men 
was independently associated with increased risk of 
IHD, stroke and ASCVD. The concentration of cholesterol 
in Korean men did not modify the effect of smoking on 
ASCVD.
IntrODuCtIOn  
Atherosclerotic cardiovascular diseases 
(ASCVD) are the leading cause of death glob-
ally, with more people dying from ASCVD 
than any other causes of death annually. A 
total of 17.7 million people died as a result 
of ASCVDs in 2015 globally, comprising 31% 
of all deaths. Of these deaths, 7.4 million are 
estimated to have been the result of coro-
nary heart disease, while 6.7 million were 
due to stroke.1 According to previous studies 
published in the western countries, tobacco 
use has been reported to be a major risk 
factor for ASCVD following hypertension.1
A growing concern is that for young adults, 
cigarette smoking may be the first leading 
cause of ASCVD, owing to the high preva-
lence of cigarette smoking in comparison to 
lower levels of alternate risk factors, including 
hypertension, diabetes and high choles-
terol levels. However, despite these observa-
tions, there remain only a small number of 
studies considering the relationship between 
smoking and ASCVD in Korea and other 
countries in East Asia.2–5
Furthermore, comparisons with Western 
populations may be less informative owing 
to the relatively lower levels of cholesterol 
commonly present in Asian countries. Biolog-
ical studies have explored the interaction 
between smoking and serum cholesterol 
levels.6–9 Nevertheless, very few studies have 
analysed the interaction effects of smoking 
and serum cholesterol on ASCVD in young 
adults.
‘World No Tobacco Day 2018’ is a campaign, 
with the primary objective of raising aware-
ness of the link between tobacco use and 
strengths and limitations of this study
 ► Novel result from Korean young adults is that smok-
ing is the first leading cause of cardiovascular dis-
ease (CVD) while smoking is the second leading 
cause of CVD in middle-aged adults.
 ► The large sample size of cohort with 118 531 young 
men between 20 and 29 years of age and were fol-
lowed up for an average of 23 years.
 ► The limitations of this study include possible mea-
surement errors and the non-random sample used.
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negative health outcomes, predominantly heart and 
other cardiovascular diseases (CVDs) including stroke. It 
will also seek to expand the range of potential strategies 
key public actors such as governmental and public bodies 
can take to reduce the health risks of tobacco use. If there 
is an established link between tobacco smoking in young 
adults and CVD, the campaign will further increase aware-
ness on smoking in young adults. The government and 
the public can then subsequently take actions to reduce 
risks of smoking at earlier stage. Unfortunately, however, 
the association between smoking and CVD in young 
adults has not received much attention because at least 
a long-term (over 20 years) follow-up study is needed. 
This serves as motivation for this study, in which we aimed 
to examine the effect of smoking on risk of ASCVD in 
Korean young adults with relatively low serum cholesterol 
levels. We also investigated whether the effect of smoking 
can be modified by serum levels of cholesterol.
MethOD
study participants
In Korea, the Korean Medical Insurance Corporation 
(KMIC) provided health insurance for private school staff 
and civil servants prior to the current insurance system, 
under which it was integrated as National Health Insur-
ance.2 A total of 4 862 438 (10.7%) of the Korean popula-
tion were covered by KMIC insurance, of which 1 297 833 
were employees, and 3 364 605 were dependents. All 
insured participants are required to participate in a bien-
nial health check-up.2 Approximately 94% of the insured 
participants in 1992 and 1994 were examined bienni-
ally. We established a prospective cohort for participants 
(aged 20–29 years) who routinely responded to the ques-
tionnaire on disease risk factors and chronic diseases, 
naming this study the Korean Life Course Health Study 
(KLCHS). The KLCHS cohort included 307 041 Koreans 
(142 461 males, 164 580 females) who were screened by 
KMIC in 1992 and 1994. Of these participants, 205 840 
(67.0%) were registered in 1992 and 101 201 (33.0%) 
were registered in 1994.
Of these 307 041 participants, 71 760 (23.4%) who 
had incomplete data height, blood pressure, fasting 
glucose, total cholesterol or body mass index (BMI) were 
excluded. We also excluded 6170 people from our anal-
ysis who reported a medical history of cancer and ASCVD, 
as well as 2091 people who had missing information on 
smoking, exercise or alcohol drinking, and 65 people who 
died before start of follow-up. Female participants were 
excluded, because of the low prevalence of smoking for 
females in Korea, resulting in a total of 118 531 eligible 
participants for the analysis. This study was a retrospec-
tive cohort using past routine laboratory data and did not 
receive consent.
Data collection
The biennial KMIC screening was provided at local 
hospitals by medical practitioners according to standard 
protocols. During the 2 year interval examination from 
1992 to 2008, we examined the variables related to the 
lifestyle of participants, such as daily smoking amount, 
duration of smoking and variables related to drinking. 
From data collected at baseline, participants were defined 
as ‘current smokers’ if they were smoking currently, ‘never 
smokers’ if they had no prior history of smoking and 
‘ex-smokers’ if they had previously smoked but at the time 
of measurement did not smoke. Current smokers were 
further categorised by amount of cigarettes consumed on 
average per day (1–9, 10–19 and 20 or greater) as well as 
duration of smoking (1–9, 10–19 and 20 or more years) 
following the example of previous studies.2 10 11
The definition of hypertension was a systolic 
BP ≥140 mmHg or diastolic BP ≥90 mm Hg.12 BMI was 
measured as weight (kg)/height (m2). Serum total choles-
terol was grouped as desirable (<200 mg/dL), border-
line-high (200–239 mg/dL) and high (≥240 mg/dL).13 
Definition of diabetes was fasting blood glucose ≥126 mg/
dL.14
Follow-up and outcomes
The main outcome variables used in the analysis were 
morbidity and mortality categorised by ischaemic heart 
disease (IHD), stroke and ASCVD. For IHD, alone (ICD 
(International Classification of Diseases) 10 codes, I20–
I25), acute myocardial infarction (AMI) alone (I21) and 
angina pectoris alone (ICD 10 codes, I20) are used. For 
stroke, stroke alone (I60–I69) was used. Finally, with 
regard to ASCVD, we used total ASCVD, including disease 
of hypertensive (I10–I15), IHD (I20–I25), all stroke (I60–
I69), other heart disease (I44–I51), sudden death (R96) 
and other vascular disease (I70–I74).
The study outcomes were identified through diag-
nosis information recorded in hospital admission, and 
from causes of death using death certificates. The study 
follow-up was nearly 100% complete, as we were able to 
search ASCVD event data electronically by KMIC regis-
trants regarding the morbidity information of ASCVD. 
The period of follow-up was 23 years from 1 January 1993 
to 31 December 2015. Data on causes of death were avail-
able during years 1993–2015, and incidence could be 
tracked during years 1995–2015. The time frames over 
which these outcomes could be assessed varied with data 
availability (figure 1).
A validation study was conducted by 20 internists 
from the Korean Society of Cardiology in 2009.15 For 
Figure 1 Timeline for data collection in the Korean Life 
Course Health Study.
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the participants who provided written permission for 
the use of their personal information, 673 CHD events 
between 1994 and 2007 were confirmed with individual 
hospital medical records, showing that 73% of desig-
nated myocardial infarctions were valid. The valida-
tion study was updated in 2013 with a value of 93%.16 
The validation study on mortality data has not been 
conducted.
statistical analysis
First, we examined relationships between smoking status 
and established ASCVD risk factors at baseline. In consid-
ering continuous ASCVD risk factors, we used ordinary 
least squares regression and coded smoking quantity as 
an ordinal variable. In this study, the Mantel Haenszel 
method was applied for dichotomous variables.17
To assess the independent effects of smoking on 
the risk of IHD, stroke and ASCVD, Cox proportional 
hazards models were used, controlling for age and the 
confounding variables such as hypertension, diabetes, 
high cholesterol and alcohol drinking. The proportional 
assumption was also tested utilising Schoenfeld resid-
uals, and the survival curve according to smoking status 
was plotted using the life-table method. We used Levins 
formula for calculating population attributable risk 
(PAR).18 In additional analyses, we excluded all events 
that had occurred in the first 4 years of follow-up. These 
analyses ensured sensitivity in our results. In all analyses, 
a two-sided significance level of 0.05 was used.
Patient and public involvement
Patients and or public were not involved.
results
The average age of the study participants was 26.7±2.0 
(SD) years. Among the 118 531 men, 78 455 (66.2%) 
were current smokers, 15 126 (12.8%) were ex-smokers 
and 92 403 (15.4) had hypertension. For total choles-
terol, 94 413 (79.7%) had a total serum cholesterol 
level <200 mg/dL, 19 764 (16.6%) had a borderline 
level of 200–240 mg/dL and 4444 (3.8%) had a level of 
240 mg/dL or higher. In terms of amount of smoking, 
28.9% smoked more than 20 cigarettes per day while 
45.5% and 25.6% of current smokers smoked 1–9 and 
10–19 cigarettes per day, respectively. Among current 
smokers, 92.0% smoked for less than 10 years while 7.6% 
and 0.4% of current smokers smoked for 10–19 years and 
more than 20 years, respectively.
Population characteristics by smoking status are 
presented in table 1. After adjusting for age, current 
smokers had a significantly higher BMI (p for 
trend=0.0056), higher consumption of alcohol drinking 
(p for trend <0.0001) and higher prevalence of diabetes 
(p for trend=0.0060) than non-smokers.
The mean length of follow-up was 23 years, for a total of 
5 191 823 person-years. During this period, 2786 (90 fatal) 
IHD cases (53/100 000 person year), stroke cases 2368 
Table 1 Baseline characteristics of the Korean Life Course Health Study, 1992–1994 according to smoking status*
Characteristics
Non-smokers
(n=24 950)
Ex-smokers
(n=15 126)
No of cigarettes per day among current smokers
1–9
(n=22 642)
10–19
(n=35 690)
≥20
(n=20 123)
P for
trend†
Age, year 26.6 (2.1) 26.9 (1.9) 26.6 (2.0) 26.8 (1.9) 26.8 (1.9) 0.1622
Systolic blood pressure, mm Hg 120.4 (11.6) 120.0 (11.8) 119.8 (11.6) 120.1 (11.6) 120.3 (11.6) 0.2558
Diastolic blood pressure mm Hg 78.0 (9.0) 77.7 (9.1) 77.5 (9.0) 77.8 (9.0) 78.0 (9.0) 0.1122
Total cholesterol, mg/dL 173.4 (32.9) 173.4 (32.6) 172.9 (33.1) 174.5 (33.4) 177.2 (34.4) 0.9543
Body mass index, kg/m2 22.3 (2.4) 22.4 (2.4) 22.3 (2.4) 22.5 (2.5) 22.9 (2.6) 0.0056
Fasting serum glucose, mg/dL 86.7 (13.3) 86.6 (13.5) 86.2 (14.1) 86.4 (14.1) 86.6 (15.3) 0.4821
Alcohol consumption, g/day 7.3 (17.7) 9.7 (19.7) 12.2 (22.6) 14.5 (25.1) 20.4 (36.1) <0.0001
Conditions, %
  Hypertension‡ 15.7 15.1 14.5 15.6 15.7 0.7987
  Hypercholesterolaemia§ 3.4 3.3 3.3 3.9 4.7 0.0743
  Diabetes¶ 0.7 0.8 0.9 0.9 1.0 0.0060
  Alcohol use** 61.2 81.3 88.2 88.3 86.9 0.1035
  Physical activity 24.9 26.8 22.9 17.5 13.0 <0.0001
*Data are expressed as means (SD) unless otherwise indicated.
†Testing for trend across nonsmokers and current smokers; ex-smokers were excluded.
‡Systolic blood pressure of at least 140 mm Hg and/or diastolic blood pressure of at least 90 mm Hg.
§Total cholesterol level of at least 6.21 mmol/L (240 mg/dL).
¶Fasting serum glucose value of at least 6.99 mmol/L (126 mg/L).
**Consumption of Soju which is a colourless distilled beverage of Korean origin.
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(126 fatal) (45.4/100 000 person year) and 6368 ASCVD 
cases (306 fatal) (122.7/100 000 person year) occurred.
The independent effects of smoking on IHD, stroke 
and ASCVD were analysed controlling for confounding 
factors through Cox proportional hazards models, as 
shown in table 2. The HR relating to IHD for current 
smokers were 1.5 (p<0.0001), and those of ex-smokers 
were 1.0 (p=0.8567). The HR of stroke was 1.4 (p<0.0001) 
for current smokers and 1.1 (p=0.5008) on ex-smokers.
Compared with non-smokers, the HR for any ASCVD 
event was 1.4 (p<0.0001) in current smokers and 1.1 
in ex-smokers (p=0.1406). Figure 2 shows the survival 
probability by smoking history (never, former, 1–9, 
10–19, ≥20 cigarette per day among current smokers) 
and the corresponding unadjusted association with 
ASCVD. The overall results demonstrated that smoking 
among young men increased the risk for ASCVD relative 
to non-smokers. After adjusting for age and traditional 
ASCVD risk factors, the HRs for IHD and stroke were 
estimated for groups classified by amount of smoking 
(figure 3A, B) and duration of smoking (figure 3C, D). 
For IHD and stroke, the risk of events increased linearly 
with higher amount of cigarette per day (p for trend, 
<0.0001 and <0.0001, respectively) and longer duration of 
smoking (p for trend, <0.0001 and <0.0001, respectively).
To examine whether serum total cholesterol levels 
could modify the effect of smoking on ASCVD, we divided 
the cohort participants into quartile of total cholesterol. 
The risks above were also found throughout the range of 
serum levels of cholesterol demonstrating that serum total 
cholesterol levels did not modify the effect of smoking on 
ASCVD (figure 4).
Estimated risk factor prevalence in current studies of 
smoking and other additional risk factors were used to 
estimate the PARs for IHD alone, stroke alone and total 
ASVCD (table 3). For IHD, current smoking accounts for 
about 24.9% of events, and hypertension accounts for 
8.1% of events. In the case of stroke, smoking was esti-
mated to account for 20.9%, while hypertension was esti-
mated to be responsible for 13.3% of stroke cases.
Table 2 Risk of morbidity from ischaemic heart disease (IHD), cerebrovascular disease (CVD) and atherosclerotic 
cardiovascular disease (ASCVD) in Korean Men in the Korean Life Course Health Study, 1992–2015*
IHD CVD ASCVD
Variables and categories HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age (5-year age group) 1.4 (1.2 to 1.6) <0.0001 1.4 (1.3 to 1.6) <0.0001 1.3 (1.2 to 1.4) <0.0001
Cigarette smoking
  Ex-smoker 1.0 (0.9 to 1.2) 0.8567 1.1 (0.9 to 1.3) 0.5008 1.1 (1.0 to 1.2) 0.1406
  Current smoker 1.5 (1.3 to 1.6) <0.0001 1.4 (1.2 to 1.6) <0.0001 1.4 (1.3 to 1.5) <0.0001
Blood pressure†
  High normal 1.2 (1.1 to 1.4) <0.0001 1.2 (1.0 to 1.3) 0.0152 1.2 (1.1 to 1.3) <0.0001
  Stage 1 hypertension 1.6 (1.4 to 1.8) <0.0001 1.7 (1.5 to 2.0) <0.0001 1.7 (1.5 to 1.8) <0.0001
  Stage 2 hypertension 2.0 (1.6 to 2.5) <0.0001 3.2 (2.5 to 4.0) <0.0001 2.9 (2.5 to 3.3) <0.0001
Total cholesterol‡
  Borderline-high 
cholesterol
1.4 (1.3 to 1.6) <0.0001 1.4 (1.3 to 1.6) <0.0001 1.4 (1.3 to 1.5) <0.0001
  High cholesterol 2.5 (2.1 to 2.8) <0.0001 1.7 (1.4 to 2.1) <0.0001 2.1 (1.8 to 2.3) <0.0001
Fasting blood sugar§
  Diabetes 1.3 (0.9 to 1.9) 0.1375 1.6 (1.1 to 2.3) 0.0222 1.5 (1.2 to 1.9) 0.0008
Physical activity
  No exercise 1.1 (1.0 to 1.3) 0.0122 1.1 (1.0 to 1.3) 0.2156 1.1 (1.0 to 1.3) 0.0075
*HRs and 95% Cls from multivariable Cox proportional hazards models.
†The reference category is normal (systolic blood pressure <140 mm Hg and diastolic blood pressure <90 mm Hg).
‡The reference category is desirable (serum cholesterol level, <5.17 mmol/L [200 mg/dL]).
§The reference category is a fasting serum glucose level of less than 6.99 mmol/L (126 mg/dL).
Figure 2 Survival of atherosclerotic cardiovascular disease 
event by smoking history in Korean young adult men, 1992–
2015.
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DIsCussIOn
Our study investigated the association between smoking 
and risk of ASCVD among Korean young men within a 
cohort study with a 23 year of follow-up. To our knowledge, 
this is the first study focusing on Korean young adults. In 
our study, smoking was the most crucial risk factor attrib-
uting to 20% of ASCVD mortality in middle age.
Diabetes, hypertension and hyperlipidaemia are well 
known risk factors for ASCVD.10 However, for young 
adults with relatively low incidence of diabetes, hyperten-
sion and hyperlipidaemia, smoking is the most important 
and an independent risk factor for predicting ASCVD in 
the present study. Furthermore, the high-smoking rate 
among young people is important with respect to the devel-
opment of middle-aged hypertension and transition to 
ASCVD.19 20 Thus, middle-aged ASCVD morbidity is likely 
predominantly predicted by smoking in young adulthood.
The body of research centred on the health effects of 
smoking is steadily increasing, with findings reported 
from many countries around the world. However, few 
studies have examined the effect of smoking on ASCVD 
in young adults.21 Here, we present evidence that current 
smoking is an independent risk factor affecting the inci-
dence of IHD, stroke and ASCVD.
These risk associations have been estimated across total 
serum cholesterol groups. A cohort study in Hasayama 
Japan found that smoking showed positive association 
with coronary heart disease in people with high levels of 
serum cholesterol above 180 mg/dL, but not with people 
with low level of cholesterol less than 180 mg/dL.22 23 
Afterward, six epidemiological studies were conducted. 
Among them, one study from Puerto Rico Heart Health 
Program24 showed similar results, but not all.7–11 Of 
Figure 3 HR with 95% CIs for ischaemic heart disease (IHD), and stroke by cigarette per day and duration of smoking. (A) IHD. 
(B) IHD. (C)Stroke. (D) Stroke. (E) Atherosclerotic c ardiovascular   disease (ASCVD). (F) ASCVD. 
Figure 4 HRs with 95% CIs for ischaemic heart disease 
(IHD) and stroke by total cholesterol groups of smokers 
compared with non-smokers: each group of total 
cholesterol levels are as follows: first, 149 mg/dL; second, 
150–169 mg/dL; third, 170–194 mg/dL and fourth, ≥195 mg/
dL. The reference group is non-smokers in each quartile 
of total cholesterol. (A) IHD. (B) Stroke. (C) Atherosclerotic 
cardiovascular  disease. 
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course, all studies were conducted among adult popula-
tions. To the best of our knowledge, no study has been 
done on young adults with much lower levels of serum 
cholesterol. In addition, the high smoking rate among 
young adults is likely to be, even directly, linked to high 
blood pressure among the adult population who devel-
oped ASCVD as a major health problem.
In this study, the non-significant risk of ASCVD among 
ex-smokers can be interpreted in two ways. First, this result 
may simply reflect the effect of smoking cessation. Most 
previous studies have shown that the effects of smoking 
cessation are immediate in CVD (most of the excess risk 
of vascular mortality due to smoking may be eliminated 
rapidly on cessation), while lung cancer occurs within 
20 years25 26. In particular, most of the excess risk of vascular 
mortality due to smoking in women may be eliminated 
rapidly on cessation and within 20 years for lung diseases.26 
Second, even if a number of young adult ex-smokers, aged 
20–29 years, may have smoked continuously from adoles-
cence, it is still a short-term of smoking, compared with 
adults. Previous study shown that reducing adult smoking 
pays more immediate dividends, both in terms of health 
improvements and cost savings.27 While present study lacks 
information on smoking duration of ex-smokers, current 
smokers who continued to smoke seem to have increased 
risk of CVD by 40%. Therefore, while the smoking duration 
of ex-smokers is unknown, it may be reasonable to consider 
the results were mainly affected by the smoking cessation. 
Further research on the effects of smoking cessation among 
young adults is necessary.
There are several studies regarding cardiovascular risk 
among young people. According to a study conducted 
by Bernaards et al,28 blood pressure and waist circum-
ference were decreased by lowering weekly tobacco 
consumption in younger participants. However, they 
did not report the risk of developing CVD events due 
to changes in smoking. This seems to be another signifi-
cant topic relating to the health of young adults. Another 
study conducted by Morotti et al21 on young women with 
polycystic ovary syndrome (PCOS) reported an associa-
tion between smoking habitude in lean PCOS patients, 
and the increase of soft markers of cardiovascular risk. 
For young adult African-Americans, the association 
between cigarette smoking and carotid intima assuming 
the genetic variation of smokers was reported and the 
−930A/G polymorphism modified the association among 
young healthy adults.29 The study on association between 
secondhand smoking among childhood and cardiovas-
cular event in adulthood was conducted and found that 
the carotid plaque risk in adulthood is increased in chil-
dren whose parents had smoked.30 31
This LCHS study has several strengths, such as high 
follow-up rates and a large, national sample. The large 
sample size of cohort allowed us to investigate the associ-
ation of smoking with various levels of serum cholesterol. 
The civil servants and private school teachers who partic-
ipated in this study accounted for about 11% of the total 
population in 1992. We did not compare the characteristics 
of the 89% population not included in the study. There-
fore, this study will not represent the whole population. 
Moreover, selection bias may be a potential issue, since the 
final sample contains a subset of over 118 531 young male 
adults (38.6%) out of 307 041 subjects initially selected for 
our study. We therefore urge conservative interpretations 
of our study results with regard to the general population.
In conclusion, smoking is a leading cause of ASCVD 
among young adults in Korea, a country with a low total 
cholesterol level and a high-smoking rate. Moreover, 
the association was not modified by total cholesterol 
level. Smoking among Korean young adult men was 
Table 3 Population attributable risks (PARs) and 95% CIs from smoking and other risk factors of ischaemic heart 
disease (IHD), cerebrovascular disease (CVD) and atherosclerotic cardiovascular disease (ASCVD) in Korean men: the Korean 
Life Course Health Study
Variables and categories Prevalence % IHD PAR (95% CI) CVD PAR (95% CI) ASCVD PAR (95% CI)
Smoking
  Current smoker 66.2 24.9 (16.6 to 28.4) 20.9 (11.7 to 28.4) 20.9 (16.5 to 24.9)
Blood pressure*
  Hypertension 22.0 8.1 (6.2 to 9.9) 13.3 (9.9 to 14.9) 9.9 (9.9 to 11.7)
Total cholesterol†
  Borderline 16.6 6.2 (4.7 to 9.1) 6.2 (4.7 to 7.7) 6.2 (4.7 to 7.6)
  High 3.8 5.4 (4.0 to 6.4) 4.0 (2.9 to 4.7) 4.0 (2.9 to 4.7)
Fasting blood sugar‡
  Diabetes 0.9 0.3 (−0.9 to 0.8) 0.5 (0.08 to 1.1) 0.4 (0.2 to 0.8)
Physical activity
  No exercise 0.8 7.4 (0 to 19.3) 7.4 (0 to 19.3) 7.4 (0 to 19.3)
*The reference category is normal (systolic blood pressure <140 mm Hg and diastolic blood pressure <90 mm Hg).
†The reference category is desirable (serum cholesterol level <5.17 mmol/L [200 mg/dL]).
‡The reference category is a fasting serum glucose level of less than 6.99 mmol/L (126 mg/dL).
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independently associated with increased risk of IHD, 
stroke and ASCVD. The concentration of cholesterol in 
Korean men did not modify the effect of smoking on 
ASCVD. Therefore, smoking cessation on young adult 
smokers is essential to prevent CVD later in adult life. 
Moreover, clinical practice guidelines and policies should 
emphasise to treat nicotine addiction in young smokers.
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